Shopping Cart 0
Cart Subtotal
USD 0

Idogen AB - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Idogen AB (Idogen) is a biotechnology company that develops tolerogenic vaccines which reprogram the immune system of paitents. The company provides product portfolio such as antibodies for autoimmune diseases, organ rejection after transplantation and several other disease conditions. It develops anti-drug antibodies against critical treatment with coagulation factor VIII (factor VIII). Idogen utilizes its platform technology to facilitate the development of tolerogenic vaccines in several areas such as hemophilia A, rheumatoid arthritis, and transplantation for type-1 diabetes. The company technology comprises a small number of dendritic cells and is treated with zebularine and the disease specific antigens. It carries out collaboration with Oxford University to develop novel therapeutic strategies for the treatment of rheumatoid arthritis. Idogen is headquartered in Lund, Sweden.

Idogen AB-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Idogen AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Idogen AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Idogen AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Idogen AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Idogen AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Idogen AB, Pharmaceuticals & Healthcare, Deal Details 10

Partnerships 10

Idogen Enters into Research Agreement with Advinus Therapeutics 10

Idogen Enters into Agreement with University of Oxford 11

Idogen Partners with Karolinska Institutet 12

Equity Offering 13

Idogen to Raise up to USD6 Million in Rights Offering of Units 13

Idogen Raises USD2 Million in IPO 14

Acquisition 15

HCN Group Acquires Minority Stake in Idogen from LU Holding 15

Idogen AB-Key Competitors 16

Idogen AB-Key Employees 17

Idogen AB-Locations And Subsidiaries 18

Head Office 18

Recent Developments 19

Financial Announcements 19

Aug 21, 2018: Idogen: Interim report January-June 2018 19

Apr 24, 2018: Idogen Reports Q1 2018 Financial Results 20

Feb 15, 2018: Idogen: Year-end report 1 January-31 December 2017 21

Corporate Communications 23

Apr 25, 2018: Idogen Names Hanne Risager Romedahl As Chief Scientific Officer 23

Mar 31, 2017: Idogen recruits Chief Medical Officer 24

Product News 25

Aug 17, 2018: Idogen extends the project portfolio to projects in autoimmune diseases 25

05/18/2017: Idogen has been granted EUR 2.9 million funding from Horizon 2020 26

05/11/2017: Tolerogenic vaccine for kidney transplantation to be next therapeutic area for Idogen 27

Product Approvals 28

Jan 16, 2017: Orphan drug designation formally granted for Idogen in Europe 28

Appendix 29

Methodology 29

About GlobalData 29

Contact Us 29

Disclaimer 29


List Of Figure

List of Figures

Idogen AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Idogen AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Idogen AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Idogen AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Idogen AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Idogen AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Idogen AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Idogen AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Idogen AB, Pharmaceuticals & Healthcare, Key Facts 2

Idogen AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Idogen AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Idogen AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Idogen AB, Deals By Therapy Area, 2012 to YTD 2018 8

Idogen AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Idogen Enters into Research Agreement with Advinus Therapeutics 10

Idogen Enters into Agreement with University of Oxford 11

Idogen Partners with Karolinska Institutet 12

Idogen to Raise up to USD6 Million in Rights Offering of Units 13

Idogen Raises USD2 Million in IPO 14

HCN Group Acquires Minority Stake in Idogen from LU Holding 15

Idogen AB, Key Competitors 16

Idogen AB, Key Employees 17

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Idogen AB, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.